| VE | Vaccine Efficacy |
|---|---|
| VFC | Vaccine for Children |
| HDCV | human diploid cell rabies vaccine |
| pneumococcal vaccine | Vaccine comprised of purified capsular polysaccharide antigen from 23 types of Streptococcus pneumoniae (representing those types responsible for most of the reported pneumococcal diseases in the U.S.). (05 Mar 2000) |
|---|---|
| poliovirus vaccine | A suspension of formalin-inactivated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used in the united states only for immunization of immunologically deficient patients and for primary immunization of unimmunised adults at risk. (12 Dec 1998) |
| poliovirus vaccine, oral | A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (12 Dec 1998) |
| polyvalent vaccine | A vaccine prepared from cultures of two or more strains of the same species or microorganism. Synonym: multivalent vaccine. (05 Mar 2000) |
| crystal violet vaccine | See: hog cholera vaccines. (05 Mar 2000) |
| Haemophilus influenza b vaccine | <virology> A vaccination that is given to infants to protect against infection with haemophilus influenza b, an important cause of neonatal sepsis. Typically administered at 2, 4, 6 and 15 months. Children who are aged 15 months to 5 years, who have not received the vaccine, should be given a single injection of haemophilus b conjugate vaccine. Acronym: HIB (26 Mar 1998) |
| Haemophilus influenzae type B vaccine | A conjugate of oligosaccharides of the capsular antigen of H. Influenzae type B and diphtheria CRM protein. (05 Mar 2000) |
| Haffkine's vaccine | A killed culture of Vibrio cholerae in two strengths, a weaker one for the initial inoculation and a stronger one for the second inoculation 7 to 10 days after the first, a killed plague bacillus (Yersinia pestis) vaccine. (05 Mar 2000) |
| sabin vaccine | Oral Polio virus Vaccine (OPV). The polio virus in opv is attenuated (weakened). The sabin vaccine is named after the american virologist albert sabin. See immunization, polio. (12 Dec 1998) |
| salk vaccine | Inactivated Polio Vaccine (IPV). The polio virus in ipv has been inactivated (killed). The salk vaccine is named after the american physician-virologist jonas salk. See immunization, polio. (12 Dec 1998) |
| hepatitis B vaccine | <virology> An injectable vaccine, given in three boosters, which offers protection from infection with hepatitis B. (27 Sep 1997) |
| heterogenous vaccine | Vaccine that is not autogenous, but is prepared from the same species of bacterium. (05 Mar 2000) |
| hib vaccine | A vaccination that is given to infants to protect against infection with haemophilus influenza b, an important cause of neonatal sepsis. Typically administered at 2, 4, 6 and 15 months. Children who are aged 15 months to 5 years, who have not received the vaccine, should be given a single injection of haemophilus b conjugate vaccine. (27 Sep 1997) |
| high-egg-passage vaccine | Living Flury strain rabies virus at the 180th to 190th level egg passage (embryonate eggs), used for vaccination of cattle and cats, low-egg-passage (LEP) vaccine: at the 40th to 50th passage level, containing 103 to 104 mouse LD50; nonpathogenic in dogs but retains some pathogenicity for cattle and cats. (05 Mar 2000) |
| Semple vaccine | A modification of the original (Pasteur) rabies vaccine, formerly widely used in the U.S., prepared from rabbit nerve tissue, inactivated with phenol and administered in 14 to 21 daily injections; has variable potency and is associated with a high incidence of postvaccinal demyelination. (05 Mar 2000) |